IPOs and Secondaries
IPOs and Secondaries Articles
Clearside Biomedical expects to price 4 million shares in the range of $14 to $16 per share in an initial public offering valued up to more than $73 million.
Published:
Last Updated:
Albertsons expects to price more than 65 million shares in the range of $23 to $26 for an initial public offering valued up to almost $2 billion.
Published:
Last Updated:
Midland States Bancorp expects to price its less than 4 million shares in the range of $25 to $27 per share in an initial public offering valued up to approximately $120 million.
Published:
Last Updated:
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
HCP has seen a positive news reaction from investors on word that it will spin off its HCR ManorCare portfolio of skilled nursing and assisted living assets into an new publicly traded REIT.
Published:
Last Updated:
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.
Published:
Last Updated:
Performance Food Group is planning to sell 12 million shares in a secondary offering valued up to roughly $370 million.
Published:
Last Updated:
U.S. Foods Holding has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Cotiviti Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Just two of four scheduled initial public offerings (IPOs) went off as planned last week and four more plus one re-try are on the calendar for the coming week. Of the coming week’s new offerings...
Published:
Last Updated:
Intellia Therapeutics entered the market with a bang on Friday, blowing out its expected price range of $16 to $18.
Published:
Last Updated:
Amplify Snack Brands Inc. (NYSE: BETR) has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its secondary offering. The company came public in August of 2015. Although no...
Published:
Last Updated:
Atkore International has amended it filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Intellia Therapeutics expects to price 5 million shares in the range of $16 to $18 apiece in an initial public offering valued up to more than $103 million.
Published:
Last Updated:
Oncobiologics expects to price 5 million shares within the range of $11 to $13 per share in an initial public offering valued up to mroe than $74 million.
Published:
Last Updated: